BioNTech presented new Phase 2 clinical trial data at ESMO 2026 showing promising results for pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, combined with chemotherapy in treating advanced cancers including metastatic non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, and neuroendocrine neoplasms. The data highlight pumitamig's potential as a backbone for novel combination therapies across multiple tumor types, including brain metastases cases where treatment options are limited. Additionally, early results from combining pumitamig with elfetabart drozuntecan, a B7-H3-targeted antibody-drug conjugate, showed encouraging antitumor activity and manageable safety in advanced solid tumors. These findings support BioNTech's strategy to develop innovative, multi-tumor cancer treatments and advance their late-stage oncology pipeline.
BioNTech's stock is trading at USD 87.78 on Pluang as of Oct 19, 2026 18:01 WIB, close to its 52-week low of USD 83.89 and well below the 52-week high of USD 119.34. The stock's 1-day change is a modest +0.08%, indicating relatively stable trading despite the promising oncology pipeline updates. This contrasts with the significant potential seen in BioNTech's late-stage clinical developments presented at ESMO 2026.
Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology eff...
Moderna shares surged 6% amid a broader market rotation from AI and tech stocks into healthcare, outperforming peers BioNTech and Pfizer. This rally is supported by positive clinical data from August showing Moderna's personalized mRNA cancer vaccine...
BioNTech's stock fell 7.13% after its Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab failed to meet the primary endpoint for progression-free survival. This setback has shaken investor confidence in BioNTech's mRNA oncology pipeline and tri...
